Ticker Details
ADMA Biologics Inc ADMA Biologics Inc is a biopharmaceutical company. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases.
IPO Date:	October 18, 2013
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$4.19B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.16 | 2.74%
Avg Daily Range (30 D):	$0.35 | 1.85%
Avg Daily Range (90 D):	$0.35 | 2.09%

Institutional Daily Volume
Avg Daily Volume:	1.62M
Avg Daily Volume (30 D):	1.81M
Avg Daily Volume (90 D):	2.55M

Trade Size
Avg Trade Size (Sh.):	178
Avg Trade Size (Sh.) (30 D):	77
Avg Trade Size (Sh.) (90 D):	86

Institutional Trades
Total Institutional Trades:	2,073
Avg Institutional Trade:	$3.41M
Avg Institutional Trade (30 D):	$3.51M
Avg Institutional Trade (90 D):	$3.66M
Avg Institutional Trade Volume:	.31M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.61M
Avg Closing Trade (30 D):	$8.08M
Avg Closing Trade (90 D):	$8.04M
Avg Closing Volume:	500.77K

News

Dec 28, 2025 @ 5:26 PM ANI Stock Is Up 49% This Past Year, Revenue Is Sur... Source: Jonathan Ponciano

Aug 7, 2025 @ 2:00 PM Plasma Derived Medicine Market to Reach USD 37.4 B... Source: Towards Healthcare

Jul 30, 2025 @ 11:00 AM ADMA Biologics to Report Second Quarter 2025 Finan... Source: Adma Biologics, Inc.

May 6, 2025 @ 8:11 PM 3 Mid-Cap Medical Stocks Outperforming the Market Source: Marketbeat.Com

Apr 7, 2025 @ 11:00 AM ADMA Biologics Statement on Tariffs Source: N/A

Financials
	TTM	Q3 2025	Q2 2025
Basic EPS	$.89	$.15	$.14
Diluted EPS	$.86	$.15	$.14
Revenue	$488.56M	$134.22M	$121.98M
Gross Profit	$267.28M	$75.63M	$67.23M
Net Income / Loss	$209.45M	$36.43M	$34.22M
Operating Income / Loss	$167.02M	$51.01M	$42.8M
Cost of Revenue	$221.28M	$58.6M	$54.76M
Net Cash Flow	$-25.32M	$-28.9M	$18.66M
PE Ratio	19.79